The GLIOMATCH project kick-off meeting took place from 25-27 March 2024 and was hosted by KU Leuven, the project coordinator, at the Faculty Club in Leuven, Belgium. This marks the first in-person gathering of the project’s 14 partner institutions.
The kick-off meeting hosted by the EC brought together six projects – ARTURO, GLIOMATCH, HIT-GLIO, MULTIR, SPACETIME and THRIVE – collaborting under the EU Cancer Mission‘s Understanding Cancer. During this meeting, the projects discussed their common goals and work plan. More information on: https://gliomatch.eu/cluster/
The GLIOMATCH 2nd consortium meeting was held online in September 2024 and focused on discussing work progress in scientific work packages.
The first annual meeting of the EU Cancer Mission‘s Understanding (tumour-host interactions) Cluster held in January 2025 brought together leading cancer researchers, policymakers, and patient representatives at IDIBAPS’ Esther Koplowitz Centre in Barcelona. The event, organised by the THRIVE project, aimed to strengthen collaboration and shape policies to advance Europe’s fight against cancer, in line […]
From 25 to 27 March 2025, the GLIOMATCH consortium convened in Düsseldorf, Germany, for its third consortium meeting. The meeting was held in-person and hosted by the partner University of Düsseldorf (UDUS). Over 40 experts from across Europe gathered to assess progress of the past year and plan the next phase of the GLIOMATCH project.
The 4th GLIOMATCH consortium meeting is held online on 17 November 2025 and focuses on scientific discussions and stakeholder involvement, including the distribution of the GLIOMATCH patient survey.
Make your plans to attend the 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, held in conjunction with the 30th Society for Neuro-Oncology Annual Meeting & Education Day in beautiful Honolulu, Hawaii! This year’s meeting is particularly special, as we celebrate SNO’s 30th anniversary—a milestone that underscores three decades of progress, collaboration, and […]
Innovating Novel Combination Therapies & Maximising Preclinical & Clinical Development to Improve Glioblastoma Targeting & Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in Need The glioblastoma drug development space has been energized by Merck's acquisition of Modifi Bio last December. This landmark deal has sparked renewed hope in a field long challenged […]
The 2nd annual meeting of the U-THI-Clust is held in Warsaw, Poland and hosted by HIT-GLIO at the Nencki Institute.
